A cure for human immunodeficiency virus type-1 (HIV-1) has been hampered by the limitation of current combination antiretroviral therapy (cART) to address the latent reservoirs in HIV-1 patients. One strategy proposed to eradicate these reservoirs is the "shock and kill" approach, where latency-reversing agents (LRAs) are used to reactivate and promote viral cell death and/or immune killing of reactivated cells.Here, we report that curaxin CBL0137, an antitumor compound, can potentiate tumor necrosis factor-α-mediated reactivation of latently infected HIV-1cell lines.Additionally, the single use of CBL0137 is sufficient to reactivate HIV-1 latent reservoirs in peripheral mononuclear cells (PBMCs) isolated from HIV-1 positive, cART-treated, aviremic patients. Thus, CBL0137 possesses capabilities as a LRA and could be considered for the "shock and kill" approach. K E Y W O R D S curaxins, facilitates chromatin transcription complex, HIV-1 latency, human immunodeficiency virus type 1, latency-reversing agents 1 | INTRODUCTION Since the implementation of combination antiretroviral therapy (cART), rates of human immunodeficiency virus type-1 (HIV-1)mortality, morbidity, and newly acquired infections have decrease drastically. 1 However, long-term therapy is still required because the virus established a reversible state of latency in memory CD4 + T cells. To address these reservoirs, two main strategies are being investigated. First, the "shock and kill" approach aims to purge the latent reservoirs by inducing renewed viral transcription/reactivation using latency-reversing agents (LRAs) to favor viral cytopathic cell death and immune clearance. Second, another strategy coined the "block and lock" approach focuses on the development of latencypromoting agents (LPAs) to instead induce a deep state of HIV-1 resulting in permanent silencing of latently infected cells and lead to their potential decay overtime. In that regard, we have previously implicated the facilitates chromatin transcription (FACT) complex as a negative regulator of HIV-1 latency. 2 Furthermore, we showed in an earlier publication that curaxin 100 (CBL0100), a compound first described as an antitumor drug that targets FACT, is a promising LPA by targeting HIV-1 transcriptional elongation. 3,4 Interestingly, another curaxin, CBL0137, has been implicated in promoting HIV integration. Its mechanism of action involves FACT-mediated destabilization of chromatin nucleosomes to favor viral genome J Med Virol. 2019;91:1571-1576.wileyonlinelibrary.com/journal/jmv